Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS-CoV-2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS-CoV-2 IgG anti-RBD titers after vaccination (comparable to B-cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B-cell depleted patients with MS. ANN NEUROL 2023;93:103–108.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalAnnals of neurology
Issue number1
Early online date2022
Publication statusPublished - Jan 2023


  • Antibodies, Viral
  • COVID-19
  • COVID-19 Vaccines
  • Humans
  • Multiple Sclerosis/drug therapy
  • SARS-CoV-2

Cite this